

Nora Pashayan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7584745/publications.pdf>

Version: 2024-02-01

130
papers

6,096
citations

87888

38
h-index

88630

70
g-index

146
all docs

146
docs citations

146
times ranked

9755
citing authors

#	ARTICLE	IF	CITATIONS
1	Concerns About Methods Used in Modeling Study of Risk-Stratified Screening for Breast Cancer. <i>JAMA Oncology</i> , 2022, , .	7.1	3
2	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. <i>Nature Communications</i> , 2022, 13, 449.	12.8	21
3	Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 755-761.	3.9	14
4	Antiproggestins reduce epigenetic field cancerization in breast tissue of young healthy women. <i>Genome Medicine</i> , 2022, 14, .	8.2	10
5	Gynecologic Cancer Risk and Genetics: Informing an Ideal Model of Gynecologic Cancer Prevention. <i>Current Oncology</i> , 2022, 29, 4632-4646.	2.2	1
6	Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction. <i>Nature Genetics</i> , 2021, 53, 65-75.	21.4	264
7	Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 532-541.	3.9	16
8	Polygenic hazard score is associated with prostate cancer in multi-ethnic populations. <i>Nature Communications</i> , 2021, 12, 1236.	12.8	40
9	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. <i>Journal of Personalized Medicine</i> , 2021, 11, 95.	2.5	28
10	Alcohol Intake and Alcohol-SNP Interactions Associated with Prostate Cancer Aggressiveness. <i>Journal of Clinical Medicine</i> , 2021, 10, 553.	2.4	3
11	Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer. <i>JAMA Network Open</i> , 2021, 4, e2037657.	5.9	34
12	Chronic Baseline Prostate Inflammation is Associated with Lower Tumor Grade in Men with Prostate Cancer on Repeat Biopsy: Results from the REDUCE Study. Letter.. <i>Journal of Urology</i> , 2021, 205, 1233-1234.	0.4	0
13	KLK3 SNP-SNP interactions for prediction of prostate cancer aggressiveness. <i>Scientific Reports</i> , 2021, 11, 9264.	3.3	5
14	Followup of Men with PI-RADS TM 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter.. <i>Journal of Urology</i> , 2021, 205, 1526-1528.	0.4	0
15	A multistate survival model of the natural history of cancer using data from screened and unscreened population. <i>Statistics in Medicine</i> , 2021, 40, 3791-3807.	1.6	3
16	Mapping PSA density to outcome of MRI-based active surveillance for prostate cancer through joint longitudinal-survival models. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 1028-1031.	3.9	10
17	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&#amp;l). <i>Journal of Personalized Medicine</i> , 2021, 11, 511.	2.5	59
18	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. <i>Journal of Personalized Medicine</i> , 2021, 11, 726.	2.5	5

#	ARTICLE	IF	CITATIONS
19	Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. <i>European Journal of Epidemiology</i> , 2021, 36, 913-925.	5.7	23
20	Potential of polygenic risk scores for improving population estimates of women's breast cancer genetic risks. <i>Genetics in Medicine</i> , 2021, 23, 2114-2121.	2.4	9
21	Of Screening, Stratification, and Scores. <i>Journal of Personalized Medicine</i> , 2021, 11, 736.	2.5	13
22	Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies. <i>European Journal of Health Economics</i> , 2021, 22, 1311-1344.	2.8	18
23	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. <i>Journal of Personalized Medicine</i> , 2021, 11, 916.	2.5	8
24	Interruption of cancer screening services due to COVID-19 pandemic: lessons from previous disasters. <i>Preventive Medicine Reports</i> , 2021, 23, 101399.	1.8	11
25	The impact of the Covid-19 pandemic on breast cancer early detection and screening. <i>Preventive Medicine</i> , 2021, 151, 106585.	3.4	68
26	Prevention in the age of personal responsibility: epigenetic risk-predictive screening for female cancers as a case study. <i>Journal of Medical Ethics</i> , 2021, 47, e46-e46.	1.8	4
27	Attitudes towards risk-stratified breast cancer screening among women in England: A cross-sectional survey. <i>Journal of Medical Screening</i> , 2020, 27, 138-145.	2.3	35
28	Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer—A Systematic Review. <i>Cancers</i> , 2020, 12, 1874.	3.7	9
29	An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk. <i>Nature Communications</i> , 2020, 11, 3905.	12.8	28
30	A cross-sectional study using the Childhood Measurement Programme for Wales to examine population-level risk factors associated with childhood obesity. <i>Public Health Nutrition</i> , 2020, 24, 1-9.	2.2	1
31	The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor. <i>Cancers</i> , 2020, 12, 3254.	3.7	16
32	The challenge of early detection in cancer. <i>Science</i> , 2020, 368, 589-590.	12.6	70
33	The effect of sample size on polygenic hazard models for prostate cancer. <i>European Journal of Human Genetics</i> , 2020, 28, 1467-1475.	2.8	14
34	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 687-705.	27.6	178
35	Peridiagnostic and cascade cancer genetic testing. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 277-278.	27.6	2
36	A Genetic Risk Score to Personalize Prostate Cancer Screening, Applied to Population Data. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1731-1738.	2.5	27

#	ARTICLE	IF	CITATIONS
37	When evidence says no: gynaecologistsâ€™ reasons for (not) recommending ineffective ovarian cancer screening. <i>BMJ Quality and Safety</i> , 2020, 29, 521-524.	3.7	5
38	A Systematic Review on Cost-effectiveness Studies Evaluating Ovarian Cancer Early Detection and Prevention Strategies. <i>Cancer Prevention Research</i> , 2020, 13, 429-442.	1.5	10
39	Runs of homozygosity and testicular cancer risk. <i>Andrology</i> , 2019, 7, 555-564.	3.5	5
40	Shared heritability and functional enrichment across six solid cancers. <i>Nature Communications</i> , 2019, 10, 431.	12.8	88
41	Overestimation of the Benefit-to-Harm Ratio of Risk-Based Mammography Screening in the United Kingdomâ€™ Reply. <i>JAMA Oncology</i> , 2019, 5, 428.	7.1	1
42	Womenâ€™s perception, attitudes, and intended behavior towards predictive epigenetic risk testing for female cancers in 5 European countries: a cross-sectional online survey. <i>BMC Public Health</i> , 2019, 19, 667.	2.9	9
43	Do cancer risk and benefitâ€™harm ratios influence womenâ€™s consideration of risk-reducing mastectomy? A scenario-based experiment in five European countries. <i>PLoS ONE</i> , 2019, 14, e0218188.	2.5	4
44	Association analyses identify 31 new risk loci for colorectal cancer susceptibility. <i>Nature Communications</i> , 2019, 10, 2154.	12.8	172
45	Childhood experiences of parenting and age at menarche, age at menopause and duration of reproductive lifespan: Evidence from the English Longitudinal Study of Ageing. <i>Maturitas</i> , 2019, 122, 66-72.	2.4	17
46	A response to â€™Personalised medicine and population health: breast and ovarian cancerâ€™. <i>Human Genetics</i> , 2019, 138, 287-289.	3.8	14
47	Polygenic risk-tailored screening for prostate cancer: A benefitâ€™harm and cost-effectiveness modelling study. <i>PLoS Medicine</i> , 2019, 16, e1002998.	8.4	56
48	Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 208-216.	2.5	21
49	Title is missing!. , 2019, 16, e1002998.		0
50	Title is missing!. , 2019, 16, e1002998.		0
51	Title is missing!. , 2019, 16, e1002998.		0
52	Title is missing!. , 2019, 16, e1002998.		0
53	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 292-309.	27.6	129
54	Prediction models for endometrial cancer for the general population or symptomatic women: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 126, 92-99.	4.4	23

#	ARTICLE	IF	CITATIONS
55	Genome-wide association study identifies susceptibility loci for B-cell childhood acute lymphoblastic leukemia. <i>Nature Communications</i> , 2018, 9, 1340.	12.8	58
56	Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts. <i>BMJ: British Medical Journal</i> , 2018, 360, j5757.	2.3	153
57	Predictive accuracy of combined genetic and environmental risk scores. <i>Genetic Epidemiology</i> , 2018, 42, 4-19.	1.3	32
58	Germline variation at 8q24 and prostate cancer risk in men of European ancestry. <i>Nature Communications</i> , 2018, 9, 4616.	12.8	43
59	Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma. <i>Nature Communications</i> , 2018, 9, 3707.	12.8	86
60	Genome-wide association study implicates immune dysfunction in the development of Hodgkin lymphoma. <i>Blood</i> , 2018, 132, 2040-2052.	1.4	17
61	Ethical, Legal, and Regulatory Issues for the Implementation of Omics-Based Risk Prediction of Women's Cancer: Points to Consider. <i>Public Health Genomics</i> , 2018, 21, 37-44.	1.0	13
62	Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer. <i>JAMA Oncology</i> , 2018, 4, 1504.	7.1	199
63	Large-scale Analysis Demonstrates Familial Testicular Cancer to have Polygenic Aetiology. <i>European Urology</i> , 2018, 74, 248-252.	1.9	20
64	Trends in lung cancer emergency presentation in England, 2006–2013: is there a pattern by general practice?. <i>BMC Cancer</i> , 2018, 18, 615.	2.6	4
65	AA9int: SNP interaction pattern search using non-hierarchical additive model set. <i>Bioinformatics</i> , 2018, 34, 4141-4150.	4.1	3
66	Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci. <i>Nature Genetics</i> , 2018, 50, 928-936.	21.4	652
67	Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants. <i>Nature Communications</i> , 2018, 9, 2256.	12.8	88
68	Validation of loci at 2q14.2 and 15q21.3 as risk factors for testicular cancer. <i>Oncotarget</i> , 2018, 9, 12630-12638.	1.8	8
69	SNP interaction pattern identifier (SIPI): an intensive search for SNP–SNP interaction patterns. <i>Bioinformatics</i> , 2017, 33, 822-833.	4.1	11
70	Identification of 19 new risk loci and potential regulatory mechanisms influencing susceptibility to testicular germ cell tumor. <i>Nature Genetics</i> , 2017, 49, 1133-1140.	21.4	120
71	Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2017, 117, 734-743.	6.4	7
72	Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. <i>Nature Communications</i> , 2017, 8, 1892.	12.8	40

#	ARTICLE	IF	CITATIONS
73	Investigating the possible causal role of coffee consumption with prostate cancer risk and progression using Mendelian randomization analysis. <i>International Journal of Cancer</i> , 2017, 140, 322-328.	5.1	17
74	Alcohol consumption and prostate cancer incidence and progression: A Mendelian randomisation study. <i>International Journal of Cancer</i> , 2017, 140, 75-85.	5.1	28
75	Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. <i>Health and Quality of Life Outcomes</i> , 2016, 14, 60.	2.4	44
76	Polyunsaturated fatty acids and prostate cancer risk: a Mendelian randomisation analysis from the PRACTICAL consortium. <i>British Journal of Cancer</i> , 2016, 115, 624-631.	6.4	23
77	Population-Based Precision Cancer Screening: A Symposium on Evidence, Epidemiology, and Next Steps. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1449-1455.	2.5	43
78	Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: Genetic variants as instruments for circulating levels. <i>International Journal of Cancer</i> , 2016, 139, 1520-1533.	5.1	26
79	Blood lipids and prostate cancer: a Mendelian randomization analysis. <i>Cancer Medicine</i> , 2016, 5, 1125-1136.	2.8	68
80	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. <i>Cancer Discovery</i> , 2016, 6, 1052-1067.	9.4	157
81	<i>Annals</i> Graphic Medicine - Living on Benefits: How Cancer Screening Is Portrayed in the U.K. National Press. <i>Annals of Internal Medicine</i> , 2016, 164, W13.	3.9	0
82	Atlas of prostate cancer heritability in European and African-American men pinpoints tissue-specific regulation. <i>Nature Communications</i> , 2016, 7, 10979.	12.8	50
83	Pubertal development and prostate cancer risk: Mendelian randomization study in a population-based cohort. <i>BMC Medicine</i> , 2016, 14, 66.	5.5	42
84	Multidisciplinary team meetings in community mental health: a systematic review of their functions. <i>Mental Health Review Journal</i> , 2016, 21, 119-140.	0.7	10
85	Evaluation of recruitment and selection for specialty training in public health: interim results of a prospective cohort study to measure the predictive validity of the selection process. <i>Journal of Public Health</i> , 2016, 38, e194-e200.	1.8	9
86	Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. <i>Personalized Medicine</i> , 2016, 13, 93-95.	1.5	21
87	Prediction of individual genetic risk to prostate cancer using a polygenic score. <i>Prostate</i> , 2015, 75, 1467-1474.	2.3	54
88	Do Health Professionals Need Additional Competencies for Stratified Cancer Prevention Based on Genetic Risk Profiling?. <i>Journal of Personalized Medicine</i> , 2015, 5, 191-212.	2.5	18
89	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1121-1129.	2.5	56
90	The effects of height and BMI on prostate cancer incidence and mortality: a Mendelian randomization study in 20,848 cases and 20,214 controls from the PRACTICAL consortium. <i>Cancer Causes and Control</i> , 2015, 26, 1603-1616.	1.8	77

#	ARTICLE	IF	CITATIONS
91	Multiple novel prostate cancer susceptibility signals identified by fine-mapping of known risk loci among Europeans. <i>Human Molecular Genetics</i> , 2015, 24, 5589-5602.	2.9	67
92	Reducing overdiagnosis by polygenic risk-stratified screening: findings from the Finnish section of the ERSPC. <i>British Journal of Cancer</i> , 2015, 113, 1086-1093.	6.4	32
93	Genome-Wide Association Study of Prostate Cancerâ€™Specific Survival. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1796-1800.	2.5	27
94	Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. <i>Genetics in Medicine</i> , 2015, 17, 789-795.	2.4	87
95	Adjusting the frequency of mammography screening on the basis of genetic risk: Attitudes among women in the UK. <i>Breast</i> , 2015, 24, 237-241.	2.2	48
96	What ethical and legal principles should guide the genotyping of children as part of a personalised screening programme for common cancer?. <i>Journal of Medical Ethics</i> , 2014, 40, 163-167.	1.8	15
97	Life insurance: genomic stratification and risk classification. <i>European Journal of Human Genetics</i> , 2014, 22, 575-579.	2.8	41
98	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
99	Preconception Healthcare Delivery at a Population Level: Construction of Public Health Models of Preconception Care. <i>Maternal and Child Health Journal</i> , 2014, 18, 1512-1531.	1.5	48
100	Preconception Healthcare and Congenital Disorders: Systematic Review of the Effectiveness of Preconception Care Programs in the Prevention of Congenital Disorders. <i>Maternal and Child Health Journal</i> , 2014, 18, 1354-1379.	1.5	38
101	Personalized screening for cancers: should we consider polygenic profiling?. <i>Personalized Medicine</i> , 2013, 10, 511-513.	1.5	10
102	Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. <i>Nature Genetics</i> , 2013, 45, 385-391.	21.4	492
103	Incorporating genomics into breast and prostate cancer screening: assessing the implications. <i>Genetics in Medicine</i> , 2013, 15, 423-432.	2.4	81
104	Cost effectiveness of the NHS breast screening programme: life table model. <i>BMJ</i> , The, 2013, 346, f2618-f2618.	6.0	70
105	Public health implications from COGS and potential for risk stratification and screening. <i>Nature Genetics</i> , 2013, 45, 349-351.	21.4	108
106	Public health genomics and personalized prevention: lessons from the <sc>COGS</sc> project. <i>Journal of Internal Medicine</i> , 2013, 274, 451-456.	6.0	28
107	Preconception health care and congenital disorders: mathematical modelling of the impact of a preconception care programme on congenital disorders. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2013, 120, 555-567.	2.3	12
108	Population-based screening in the era of genomics. <i>Personalized Medicine</i> , 2012, 9, 451-455.	1.5	21

#	ARTICLE	IF	CITATIONS
109	Measuring health: A practical challenge with a philosophical solution?. <i>Maturitas</i> , 2011, 68, 210-216.	2.4	8
110	Cervical cancer in Indigenous women: The case of Australia. <i>Maturitas</i> , 2011, 70, 234-245.	2.4	13
111	Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. <i>British Journal of Cancer</i> , 2011, 104, 1656-1663.	6.4	153
112	Translating genomics into improved population screening: hype or hope?. <i>Human Genetics</i> , 2011, 130, 19-21.	3.8	7
113	PSA-detected prostate cancer and the potential for dedifferentiation—estimating the proportion capable of progression. <i>International Journal of Cancer</i> , 2011, 128, 1462-1470.	5.1	14
114	Validation of a modelling approach for estimating the likely effectiveness of cancer screening using cancer data on prevalence screening and incidence. <i>Cancer Epidemiology</i> , 2011, 35, 139-144.	1.9	4
115	Age-“period” cohort analysis of colorectal cancer in East Anglia, 1971-2005. <i>Cancer Epidemiology</i> , 2010, 34, 232-237.	1.9	6
116	Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: implications of sojourn time on screening. <i>British Journal of Cancer</i> , 2009, 100, 1198-1204.	6.4	58
117	Stage Shift in Psa-detected Prostate Cancers — Effect Modification by Gleason Score. <i>Journal of Medical Screening</i> , 2009, 16, 98-101.	2.3	19
118	Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. <i>BMC Urology</i> , 2009, 9, 7.	1.4	20
119	Mortality attributable to excess adiposity in England and Wales in 2003 and 2015: explorations with a spreadsheet implementation of the Comparative Risk Assessment methodology. <i>Population Health Metrics</i> , 2009, 7, 11.	2.7	11
120	Selection into specialty training in public health: performance of the Medical Training Application Service shortlisting. <i>Journal of Public Health</i> , 2007, 29, 331-337.	1.8	6
121	Avoiding bias from aggregate measures of exposure. <i>Journal of Epidemiology and Community Health</i> , 2007, 61, 461-463.	3.7	5
122	Domestic violence: The Lebanese experience. <i>Public Health</i> , 2007, 121, 208-219.	2.9	55
123	Informal knowledge transfer in the period before formal health education programmes: case studies of mass media coverage of HIV and SIDS in England and Wales. <i>BMC Public Health</i> , 2007, 7, 293.	2.9	10
124	Sesame oil use in ameliorating cough in children: A randomised controlled trial. <i>Complementary Therapies in Medicine</i> , 2006, 14, 92-99.	2.7	9
125	Excess cases of prostate cancer and estimated overdiagnosis associated with PSA testing in East Anglia. <i>British Journal of Cancer</i> , 2006, 95, 401-405.	6.4	35
126	Incidence trends of prostate cancer in East Anglia, before and during the era of PSA diagnostic testing. <i>British Journal of Cancer</i> , 2006, 95, 398-400.	6.4	13

#	ARTICLE	IF	CITATIONS
127	Cost-effectiveness of primary offer of IVF vs. primary offer of IUI followed by IVF (for IUI failures) in couples with unexplained or mild male factor subfertility. BMC Health Services Research, 2006, 6, 80.	2.2	51
128	Survival trends for small intestinal cancer in England and Wales, 1971â€“1990: national population-based study. British Journal of Cancer, 2006, 95, 1296-1300.	6.4	5
129	Practice patterns of antiphospholipid syndrome at a tertiary teaching hospital in Lebanon. Lupus, 2002, 11, 759-764.	1.6	2
130	Routine urinalysis of patients in hospital in Lebanon: how worthwhile is it?. Journal of Medical Screening, 2002, 9, 181-186.	2.3	3